Compare · BSX vs PDEX
BSX vs PDEX
Side-by-side comparison of Boston Scientific Corporation (BSX) and Pro-Dex Inc. (PDEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and PDEX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $64.06B, about 296.9x PDEX ($215.7M).
- Over the past year, BSX is down 57.9% and PDEX is up 113.5% - PDEX leads by 171.4 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 4 for PDEX).
- BSX has more recent analyst coverage (25 ratings vs 0 for PDEX).
- Company
- Boston Scientific Corporation
- Pro-Dex Inc.
- Price
- -
- -
- Market cap
- $64.06B
- $215.7M
- 1M return
- +2.82%
- +14.44%
- 1Y return
- -57.89%
- +113.48%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 4
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Pro-Dex Inc.
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Latest BSX
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
Latest PDEX
- Pro-Dex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 8-K filed by Pro-Dex Inc.
- SEC Form 10-Q filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2027 First Quarter Results
- SEC Form DEFA14A filed by Pro-Dex Inc.
- SEC Form DEF 14A filed by Pro-Dex Inc.
- Pro-Dex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Chief Executive Officer Van Kirk Richard Lee Jr sold $45,412 worth of shares (765 units at $59.36) as part of a pre-agreed trading plan, decreasing direct ownership by 0.96% to 79,228 units (SEC Form 4)
- Chief Executive Officer Van Kirk Richard Lee Jr sold $1,165,290 worth of shares (19,235 units at $60.58) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,993 units (SEC Form 4)
- Chief Financial Officer Charlton Alisha sold $140,983 worth of shares (2,300 units at $61.30), decreasing direct ownership by 10% to 21,870 units (SEC Form 4)